The AHA appreciates the Medicare Payment Advisory Commission’s concerns about rising pharmaceutical costs and urged the Commission to continue to take action to achieve sustainable drug pricing. “Hospitals, and the clinicians who work in them, know firsthand the lifesaving potential of drug therapies … however, an unaffordable drug is not a lifesaving drug,” AHA said in a letter to MedPAC commissioners. AHA shared recommendations with MedPAC, including mandating an average sales price inflation cap for Medicare Part B and Part D drugs, and applying the cap to both high-cost and lower-cost drugs; identifying approaches to preventing excessively high launch prices as a response to an ASP inflation cap; maintaining the ASP plus 6 percent payment methodology for Part B drugs; testing a new Part D payment model that reduces or eliminates reinsurance payments while making appropriate adjustments to the direct subsidy rate; and improving annual public reports on Medicare Part B and Part D drug costs by making them more consumer and provider-friendly.

Related News Articles

Headline
The Department of Homeland Security has released a new resource to help hospitals and health systems prepare for and respond to an active shooter incident.
Chairperson's File
During Mental Health Month, let’s all remember that caring for the whole person improves health and saves lives.
Headline
he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
Headline
The Centers for Medicare…
Headline
The AHA Physician Alliance today released a resource to help hospital and health system leaders address burnout in their organizations.
Headline
The AHA has elected to fill a vacancy on its Board of Trustees Sylvia Young, president and CEO of HCA Healthcare’s Continental Division.